Last reviewed · How we verify
NCT06155786
Cognitive Effects of tDCS and tRNS in Schizophrenia
NA trial testing transcranial direct current stimulation (tDCS) active stimulator in Schizophrenia in 36 participants. Completed in 22 July 2024.
1 November 2023
Quick facts
| Lead sponsor | The National Brain Mapping Laboratory (NBML) |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 36 |
| Start date | 1 January 2023 |
| Primary completion | 1 November 2023 |
| Estimated completion | 22 July 2024 |
| Sites | 2 locations across Iran |
Drugs / interventions tested
- transcranial direct current stimulation (tDCS) active stimulator
- transcranial random noise stimulation (tRNS)
- transcranial direct current stimulation (tDCS) sham stimulator
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
The National Brain Mapping Laboratory (NBML) — full company profile →
Who can join
Adults 18 to 50, any sex, with Schizophrenia or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate the cognitive effects of different electrical stimulation modalities, such as transcranial direct and random-noise stimulation over the dorsolateral prefrontal cortex, in schizophrenia.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.
Sehatpour P, Kantrowitz JT. · · 2025 · cited 12× · PMID 39218136 · DOI 10.1016/j.biopsych.2024.08.019 -
Cognitive and emotional effects of bilateral prefrontal anodal tDCS and high-frequency tRNS in schizophrenia: a randomized sham-controlled study.
Jafari E, Moghadamzadeh A, Vaziri Z, Atadokht A, et al · · 2026 · cited 3× · PMID 41530140 · DOI 10.1038/s41537-025-00720-z
Verify or expand the search:
- PubMed search for NCT06155786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other The National Brain Mapping Laboratory (NBML) trials
Trials by the same sponsor.
- NCT06974136 — tES Modalities for the Treatment of ADHD · NA · recruiting
- NCT06740864 — 40 Hz Transcranial Alternating Current Stimulation for Inducing Gamma Oscillations · NA · completed
- NCT06401928 — Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosis · NA · completed
- NCT05200962 — Electrical Brain Stimulation for Cognitive Impairment in Schizophrenia: a tDCS-fMRI Study · Phase 1 · unknown
- NCT06680154 — Induction and Stabilization of Gamma Oscillations With 40 Hz External Brain Stimulation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06155786 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The National Brain Mapping Laboratory (NBML)
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06155786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing